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Abstract
The hypothalamic-pituitary-adrenal axis is activated in
response to stress. One of the activated hypothalamic
hormones is arginine vasopressin, a hormone involved
in hemodynamics and osmoregulation. Copeptin, the
C-terminal part of the arginine vasopressin precursor
peptide, is a sensitive and stable surrogate marker for
arginine vasopressin release. Measurement of
copeptin levels has been shown to be useful in a
variety of clinical scenarios, particularly as a prognostic
marker in patients with acute diseases such as lower
respiratory tract infection, heart disease and stroke.
The measurement of copeptin levels may provide
crucial information for risk stratification in a variety of
clinical situations. As such, the emergency department
appears to be the ideal setting for its potential use.
This review summarizes the recent progress towards
determining the prognostic and diagnostic value of
copeptin in the emergency department.
Introduction
Risk stratification is a core task in emergency medicine.
Novel biomarkers such as pro-calcitonin and copeptin
have emerged to assist clinicians with decision-making.
Elevated pro-calcitonin levels, for example, might help
to decide whether administration of antibiotics in lower
respiratory tract infections is necessary [1,2].
Arginine vasopressin (AVP), also known as antidiuretic
hormone, is one of the key hormones of the hypothalamic-
pituitary-adrenal (HPA) axis. Copeptin, a peptide of 39
amino acids, is the C-terminal part of pro-AVP and is
released together with AVP during processing of the pre-
cursor peptide (see Figure 1) [3]. Copeptin and AVP are
secreted from the neurohypophysis upon hemodynamic or
osmotic stimuli (see Figure 2). AVP is also involved in the
endocrine stress response. Corticotropin-releasing hormone
and AVP appear to have a synergistic effect, resulting in
adrenocorticotropic hormone (ACTH) and cortisol release
[4-7]. High cortisol levels reflect a higher degree of stress,
but are dependent on the integrity of the HPA-axis [8,9].
Copeptin appears to be superior to cortisol in determination
of the stress level, as cortisol is further downstream in the
stress response, has a strong circadian rhythm and is also
challenging to measure as a free hormone [10].
In contrast to AVP and cortisol, copeptin is stable both
in serum and plasma at room temperature and can be
easily measured ex vivo as a ‘shadow’ fragment of AVP in
the circulation [11,12], in manual or fully automated che-
miluminescence assays. Copeptin results are available
within one hour, which is crucial for any useful biomarker
in the emergency department (ED) setting.
This mini review outlines the potential prognostic and
diagnostic use of copeptin in the ED in the context of a
number of different possible clinical conditions and
summarizes the recent progress made in this field.
Effects of copeptin and AVP in the circulation
The physiologic function of AVP is threefold. When
released into the circulation, AVP mediates arteriolar
vasoconstriction via the V1-receptor and exhibits an anti-
diuretic effect in the kidneys via the V2-receptor [13]. A
third AVP receptor appears to be involved in the secre-
tion of ACTH [14]. At present, it is unclear if copeptin
has a physiologic effect outside the neuron, where it acts
as a chaperone in the maturation process of AVP. It is
noteworthy that, in vivo, the kinetics of copeptin are
similar to those of AVP [12,15], whilst, ex vivo,t h ep r o -
tein has an extraordinary stability of one to two weeks at
room temperature [12]. This favorable discrepancy allows
for the precise measurement of copeptin as a surrogate
marker for the unstable AVP.
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any medium, provided the original work is properly cited.Copeptin in acute myocardial infarction and heart failure
Early and safe rule-out of myocardial infarction (MI) is
crucial in the ED. Reichlin et al.e x a m i n e dt h er o l eo f
copeptin in the diagnosis of 487 consecutive patients
with chest pain presenting to the ED [16]. Copeptin
levels were already elevateda tat i m ew h e nt r o p o n i nT
was still undetectable (0 hours to 4 hours) in 20 out of
81 patients with the final diagnosis of acute MI. In their
study, negative troponin and copeptin at the time of ED
presentation was enough to rule out acute MI, with an
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Figure 1 Cartoon of the 164-amino acid peptide precursor, preprovasopressin. Shows the signal sequence (white), AVP (dark green),
neurophysin II (pale green) and copeptin (light green). Copeptin (CT-proAVP) is the C-terminal part of proAVP. Numbers indicate amino acids of
the human protein. AVP: arginine vasopressin; CT-proAVP: C-terminal proAVP; signal: signal peptide.
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Figure 2 Synthesis and release of AVP and copeptin in hypothalamus and pituitary. Pro-AVP is processed in the hypothalamus, followed
by two distinct release-mechanisms for the anterior and posterior pituitary. During stress, a drop in blood pressure, or a change in osmotic
pressure, AVP is released into the circulation. ACTH: adrenocorticotropic hormone; AVP: arginine vasopressin.
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Page 2 of 6excellent negative predictive value of 99.7% [16]. This
was confirmed in a similar study by Keller et al.[ 1 7 ] .
However, recent studies have shown an increased diag-
nostic sensitivity of high-sensitivity troponin assays com-
pared to conventional assays in the early detection of
acute MI [18,19].
At present, there is confusion on the nomenclature
and clinical use of these assays [20]. This needs to be
clarified before the benefit of additional biomarkers can
be fairly evaluated. First reports on a direct comparison
of high-sensitivity troponin assays and copeptin confirm
the additive effect [21], and the results of the ongoing
CHOPIN trial (Copeptin Helps in the early detection Of
Patients with acute myocardial INfarction), a multicen-
ter trial of 2000 patients with chest pain in the ED,
should answer many of the open questions (Clinical-
Trials.gov Identifier: NCT00952744).
In several studies, copeptin has been reported to be a
useful biomarker in patients with chronic heart failure.
High levels of copeptin predicted poor long-term prog-
nosis in patients with chronic heart failure [22,23].
When combined with B-type natriuretic peptide (BNP)
measurement, outcome prediction could be improved
further [22,23].
When copeptin was measured in 980 patients who
had experienced an acute MI, it was found to be ele-
vated in patients who died or were readmitted with
heart failure, compared with survivors. Copeptin and N-
terminal proBNP were independent predictors of death
or heart failure at 60 days, helping to stratify patients
into low-, intermediate- or high-risk groups [24]. In a
multicenter study, it was confirmed that copeptin is a
strong marker for mortality and morbidity in patients
with heart failure after an acute MI [25].
The clinical evidence in this field is increasing rapidly.
A recent study of patients treated in an outpatient clinic
for chronic stable heart failure showed that copeptin
and high-sensitivity cardiac troponin T (hs-cTnT) levels,
both single and combined, are powerful predictors of
death and hospitalization. This suggests that simulta-
neous assessment of myocardial damage and the acti-
vated vasopressin system, through single measurement
of hs-cTnT and copeptin levels, might be of prognostic
relevance [26].
Copeptin may have not only short term prognostic
relevance, but also identify patients at higher long-term
risk. Increased copeptin concentrations in elderly
patients with symptoms of heart failure were associated
with an increased risk of all-cause mortality after a
lengthy median follow-up of 13 years [27].
Finally, a secondary analysis from the Biomarkers in
Acute Heart Failure (BACH) study looked at the inter-
action of copeptin and sodium concentrations. Whilst
it is well known that low serum sodium is an indicator
of increased mortality in patients with heart failure, no
studies examined if and how the vasopressinergic sys-
tem was activated. The authors of the BACH study
now report significantly increased 90-day mortality,
readmissions and ED visits in patients with hyponatre-
mia, especially in those with elevated copeptin. Patients
with hyponatremia and low copeptin had a lower risk.
C o p e p t i nw a sh i g h l yp r o g n o s t i cf o r9 0 - d a ya d v e r s e
events in acute heart failure patients, adding prognostic
value to clinical predictors, serum sodium and
natriuretic peptides. This report is of particular interest
in the light of ongoing discussions on the potential
value of vasopressin receptor antagonists (such as tol-
vaptan) for patients with heart failure, as elevated
copeptin may identify those patients with an activated
AVP system most likely to benefit from AVP antago-
nists [28].
Copeptin in hyponatremia and diabetes insipidus
Hyponatremia is common in the ED, but the diagnostic
approach is often challenging [29]. In the differential
diagnosis of the syndrome of inappropriate antidiuretic
hormone hypersecretion and sodium depletion, copeptin
showed promising results [30]. However, a large overlap
in copeptin levels still makes the differentiation between
these two disorders challenging. In this context, the
copeptin to urinary sodium ratio was most helpful.
Further studies are needed here and currently ongoing.
In other situations of disturbed water balance, such as
diabetes insipidus, the role of copeptin was also investi-
gated. Three studies showed promising results of copep-
tin in the differential diagnosis of polydipsia-polyuria
syndrome [30-32]. However, according to a recent
study, the value of copeptin might be restricted to
patients with no further acute illness, such as stroke or
pneumonia, besides a sodium imbalance [33].
Copeptin as a prognostic marker
Besides the clinical indications mentioned so far, the
role of copeptin as a prognostic biomarker was also
examined in a variety of other indications, such as acute
exacerbations of chronic obstructive pulmonary disease
[34], lower respiratory tract infections [35], hemorrhagic
and septic shock [15], stroke [36,37] and traumatic
brain injury [38]. Table 1 summarizes the recent study
results.
Copeptin in elderly ED patients presenting with non-
specific complaints
Older patients in the ED are at risk of adverse health
outcomes [39]. Atypical disease presentation or presen-
tation with non-specific complaints, such as weakness or
fatigue, is common [40]. The attenuated physiologic
reaction of elderly patients in response to even serious
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Basel non-specific complaints (BANC) study aims to
evaluate risk-stratification tools for these, mostly elderly,
patients presenting to the ED with non-specific com-
plaints [40]. In this study, copeptin concentrations were
significantly higher in non-survivors than in survivors,
irrespective of the final diagnosis [41]. Of note, the spec-
trum of diseases underlying non-specific complaints is
extremely broad [42], suggesting that copeptin may well
be a non-specific marker for disease severity. Copeptin
was predictive of 30-day all-cause mortality and elevated
levels were associated with an increased mortality in
univariate models. Copeptin also provided independent
and additional information to clinical risk scores, such
as the Katz Index of Independence in Activities of Daily
Living and the Charlson Comorbidity Index. Copeptin
measurement might therefore facilitate level of care
decisions in the ED for this patient group [41].
Copeptin and other biomarkers
In the ED, copeptin is in competition with other novel
biomarkers that are also investigated for their potential
use as prognosticators. Apart from established cardiac
markers such as BNP, NT-proBNP and derivates of
atrial natriuretic peptide [43], other peptides (for exam-
ple mid-region pro-adrenomedullin [44], ST2 [45] and
growth-differentiation factor-15 [46]) are currently the
focus of several research groups. The jury is still out on
which markers will ultimately make it into clinical rou-
tine. The potential advantage of AVP and copeptin over
these competing markers in the ED lies in its more cen-
tral role as one of the key hormones in the body. It is
not limited to a single organ system, but is triggered by
many disease processes also outside the cardiovascular
system. This non-specificity, with respect to a precise
diagnostic role, is its strength as a more generalized
marker for severe disturbances in patient physiology. In
Table 1 Overview of studies investigating the use of copeptin in different clinical settings.
Clinical scenario Setting Number
of
patients
Outcome
AECOPD [34] ED 167 Copeptin levels > 40 pmol/L associated with prolonged hospital stay and
long-term clinical failure (death or rehospitalization for AECOPD up to six
months after inclusion).
LRTI [35] ED 545 Copeptin levels increased with increasing severity of LRTI, as classified by
the Pneumonia Severity Index
- predictive of mortality (AUC 0.75)
- copeptin levels in survivors 24.3 pmol/L (normal: 10.8 to 43.8 pmol/L),
versus 70.0 pmol/L (normal: 28.8 to 149 pmol/L) in non-survivors
- optimal threshold of copeptin, 53 pmol/L; sensitivity to correctly predict
mortality, 58% with a specificity of 80%; LR+ 3.0, LR- 0.5
Hemorrhagic and septic shock [15] ICU 101 Copeptin levels increased with disease severity from systemic inflammatory
response syndrome to sepsis and severe sepsis to septic shock
- copeptin levels in non-survivors, 171.5 pmol/L versus survivors, 86.8 pmol/
L, P < 0.001
- predictive of mortality (AUC 0.75)
- optimal prognostic accuracy of copeptin at 96 pmol/L; sensitivity, 61.5%,
specificity 83.8%
Acute ischemic stroke [49] ED 362 Copeptin
- associated with severity of stroke and lesion size
- predicts functional outcome (AUC 0.73) and mortality (AUC 0.82) after
three months
Cerebrovascular re-event after
transient ischemic attack within 90
days [36]
ED 107 - AUC for copeptin to predict re-event within 90 days, 0.73.
- at cutoff of 9.0 pmol/L for copeptin; sensitivity, 80%, specificity, 76%
One-year outcome in patients with
acute stroke [37]
One-year follow-
up on ED
patients
341 of 362 Copeptin predicts
- one-year mortality after stroke (AUC 0.74)
- functional outcome (AUC 0.72)
Acute spontaneous intracerebral
hemorrhage [50]
ED 40 Copeptin predicts
- 30-day mortality (AUC 0.88), comparable with that of GCS (AUC 0.82)
- 90-day functional outcome (AUC 0.68)
Traumatic brain injury [38] Neurosurgery 94 Copeptin
- predicts one-month mortality (AUC 0.874), similar to that of GCS
- copeptin levels > 451.8 pg/mL; sensitivity, 88.5%, specificity, 75%, in
prediction of one-month mortality
AECOPD: acute exacerbation of chronic obstructive pulmonary disease; AUC: area under the curve; ED: emergency department; GCS: Glasgow Coma Scale; ICU:
intensive care unit; LR-: negative likelihood ratio; LR+: positive likelihood ratio.
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marker panel strategies copeptin is likely to be one of
the strongest candidates.
Limitations of copeptin
As with most biomarkers there are certain confounding
factors for the interpretation of copeptin levels. Copeptin
levels were found to be higher in the male volunteers com-
pared with female. Especially in men, there is a strong
relationship between copeptin and decreased glomerular
filtration rate, probably due to decreased renal copeptin
clearance [47]. Furthermore, corticosteroids appear to
inhibit copeptin release [48].
Conclusion
AVP is a substantial part of the endocrine stress
response, resulting in ACTH and cortisol release. The
trigger for the rapid release of AVP and copeptin in
acute disease is not yet clear. Possibly, the body
responds to acute and life-threatening diseases by
immediate AVP and copeptin release. Copeptin as a bio-
marker appears to reflect the individual stress level [10].
In the ED, copeptin may be a clinically useful non-speci-
fic prognostic marker reflecting disease severity in patients
with a wide array of diseases, such as lower respiratory
tract infections, heart failure and stroke. Copeptin might
assist with risk stratification, resource allocation and dis-
position planning. However, future studies are needed to
evaluate ideal cut-off levels in these clinical scenarios.
Additionally, intervention trials are needed to show that
determination of copeptin levels in the emergency setting
improves patient care.
The concept of a readily available biomarker with the
ability to improve prognostic accuracy of known risk
stratification tools, such as risk scores, is attractive. Is
copeptin, perhaps, the long awaited biomarker that dis-
cerns ‘sick’ from ‘not sick’?
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